Vaxcyte (PCVX)
(Real Time Quote from BATS)
$83.25 USD
+1.62 (1.99%)
Updated Jul 22, 2024 11:10 AM ET
3-Hold of 5 3
D Value F Growth A Momentum D VGM
Price, Consensus and EPS Surprise
PCVX 83.25 +1.62(1.99%)
Will PCVX be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for PCVX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for PCVX
Vaxcyte, Inc. (PCVX) Is Up 2.14% in One Week: What You Should Know
The Zacks Analyst Blog Highlights HEICO, Constellation Energy, Inter Parfums, Apellis Pharmaceuticals and Vaxcyte
PCVX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Why Vaxcyte (PCVX) Might Surprise This Earnings Season
5 Stocks to Buy That Are Poised to Beat on Earnings This Week
Codexis (CDXS) Transfers Leasing Rights to Vaxcyte, Stock Up
Other News for PCVX
Russell rotation: YTD market capitalizations swelling for small-caps
ClearBridge Small Cap Growth Strategy Q2 2024 Commentary
Vaxcyte Appoints John Furey to Board of Directors
Buy Rating on Vaxcyte (PCVX) Stock: Serotype Coverage and Expanding Vaccine Recommendations Fuel Optimism
Buy Rating Affirmed for Vaxcyte Amid Promising Vaccine Developments and Market Potential